16 assets in Celiac Disease

Therapeutic assets addressing Celiac Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Kan-101 Celiac Disease	Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA	P2	BB (65)
Donq52 Celiac Disease	Chugai Pharmaceutical	P2	B (60)
Ferinject Celiac Disease	Assistance Publique - Hôpitaux de Paris	P4	B (60)
Iron Celiac Disease	Assistance Publique - Hôpitaux de Paris	P4	B (60)
Tak-062 Celiac Disease	Takeda	P2	B (57)
Tak-101 Celiac Disease	Takeda	P2	B (57)
tpm502 Celiac Disease	Topas Therapeutics GmbH	P2	B (57)
Amlitelimab Celiac Disease	Sanofi	P2	CCC (53)
fb102 Celiac Disease	Forte Biosciences, Inc.	P2	CCC (53)
Tev-53408 Celiac Disease	Teva Branded Pharmaceutical Products R&D LLC	P2	CCC (53)
Vilagletistat Celiac Disease	Dr. Falk Pharma GmbH	P2	CCC (53)
Ritlecitinib Celiac Disease	Massachusetts General Hospital	P2	CCC (52)
hb-2121 Celiac Disease	Nielsen Fernandez-Becker	P1	CC (46)
Vtp-1000 Celiac Disease	Barinthus Biotherapeutics	Early P1	C (39)
L-Tryptophan Celiac Disease	McMaster University	N/A	D (30)
Iron Hydroxide Polymaltose Celiac Disease	Kaplan Medical Center	N/A	NR ()